Aranesp
information and resources from the National Cancer Institute
Aranesp
(Other name for: darbepoetin alfa)
Darbepoetin alfa
Aranesp is indicated for the treatment of anemia in patients with non- myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy.
Amgen, Inc Jul 19 2002
Darbepoetin alfa
Treatment of anemia associated with chronic renal failure.
Amgen, Inc Sep 17 2001
|
|
|
|
news articles
POLICE ARREST LEDFORD, DAILEY,WITMER 01 Apr 2006
Harnesslink, Troopers seized what the story referred to as "significant quantities" of the drug Aranesp, said state Deputy Attorney General Christine D'Elia. ...
Amgen's Aranesp gets widened dosing schedule Mar 29, 2006
Pharmaceutical Business Review The FDA has approved a new less frequent dosing regime for Aranesp, a treatment for chemotherapy-induced anemia produced by biotech giant Amgen. ...
FDA OKs extended Aranesp dosing Mar 29, 2006
myDNA.com, The US Food and Drug Administration (FDA) has approved every-three-week dosing of Aranesp (darbepoetin alfa) for treatment of chemotherapy-induced anemia in ...
Amgen Gets New Aranesp Dosing FDA OK Mar 27, 2006
Houston Chronicle, ...largest biotechnology company, said Monday that the Food and Drug Administration approved a new, less frequent dosing regimen for its anemia treatment Aranesp. ...
New Aranesp Dosing Schedule Approved Mar 27, 2006
TheStreet.com Regulators have approved a less-frequent dosing schedule for Aranesp, the anemia drug from biotech giant Amgen (AMGN:Nasdaq - commentary - research - Cramer's ...
FDA Approves Extended Dosing Of Amgen's Aranesp To Treat ... Mar 27, 2006
Trading Markets, ...news | Powerrating), a biotechnology company, revealed that the US Food and Drug Administration has approved every-three-week dosing of Aranesp, or darbepoetin ...
Aranesp dosed every three weeks achieved and maintained target ... Mar 28, 2006
RxPG NEWS, ...therapy. Aranesp is a recombinant erythropoietic protein (a protein that stimulates production of oxygen-carrying red blood cells). ...
FDA Approves Extended Dosing of Aranesp Mar 27, 2006
International News Service, NOW, THE FDA HAS APPROVED 500 MICROGRAMS EVERY-THREE-WEEK DOSING OF ARANESP FOR CHEMOTHERAPY-INDUCED ANEMIA, WHICH CAN PROVIDE ADDED CONVENIENCE FOR PATIENTS ...
Amgen Says FDA Approves Extended Dosing Of Aranesp To Treat ... Mar 27, 2006
Trading Markets, ...(RTTNews) - Amgen (AMGN | charts | news | Powerrating) on Monday morning said it received the FDA approval for every-three-week dosing of Aranesp to treat ...
FDA Approves Extended Dosing Of Aranesp Mar 30, 2006
Medical News Today (press release), ...largest biotechnology company, today announced the US Food and Drug Administration (FDA) has approved every-three-week dosing of Aranesp® (darbepoetin alfa ...
FDA APPROVES EXTENDED DOSING OF ARANESP Mar 27, 2006
PR Newswire (press release), NOW, THE FDA HAS APPROVED 500 MICROGRAMS EVERY-THREE-WEEK DOSING OF ARANESP FOR CHEMOTHERAPY-INDUCED ANEMIA, WHICH CAN PROVIDE ADDED CONVENIENCE FOR PATIENTS ...
MultiVu Video Feed: FDA Approves Extended Dosing of Aranesp(R) to ... Mar 27, 2006
PR Newswire (press release), Now, the FDA has approved every-three-week dosing of Aranesp, a medication that increases red blood cell counts, for the treatment of chemotherapy-induced ...
FDA Approvals: Aranesp, Taxotere, Leukine Mar 28, 2006
Medscape (subscription) On March 27, the FDA approved an extended dosing regimen for darbepoetin alfa injection (Aranesp, made by Amgen, Inc), allowing the use of a 500-µg dose once ...
New Phase 2 Data Suggest Treatment of Anemia with Aranesp(R) ... Mar 13, 2006
Genetic Engineering News, Nasdaq:AMGN), the world's largest biotechnology company, announced results from a Phase 2 study that showed that treating anemia with Aranesp(R) (darbepoetin ...
Amgen Says Aranesp Could Raise Hemoglobin Level In Anemic Patients ... Mar 13, 2006
Trading Markets, ...charts | news | Powerrating), a biotechnology company, revealed that treating anemia with its unique erythropoiesis stimulating protein, Aranesp, in patients ...
Every-Three-Week Aranesp® Effective Treatment of Chemotherapy ... Mar 1, 2006
Cancer Consultants (press release), European researchers have reported that patients with chemotherapy-induced anemia can be treated safely and effectively with Aranesp (darbepoetin) administered ...
Aranesp may help treat anemia Mar 14, 2006
Ventura County Star (subscription), Aranesp, an anemia-fighting drug from Amgen Inc., has shown promise in treating anemia in patients with symptomatic heart failure, advancing the company's ...
FDA Approves Extended Dosing of Aranesp (Darbepoetin Alfa) to ... Mar 27, 2006
DG News OAKS, CA -- March 27, 2006 -- Amgen today announced the US Food and Drug Administration (FDA) has approved every-three-week dosing of Aranesp(R) (darbepoetin ...
FDA approves extended dosing of Aranesp Mar 28, 2006
RxPG NEWS, Building on this heritage, Amgen developed Aranesp, a unique erythropoiesis-stimulating protein that can be dosed less frequently. ...
Amgen's Phase 3 RED-HF(TM) Trial Will Evaluate The Clinical Effect ... Mar 19, 2006
Medical News Today (press release), Amgen announced results from a Phase 2 study that showed that treating anemia with Aranesp(R) (darbepoetin alfa) in patients with symptomatic heart failure was ...
TODAY ON PHARMALIVE.COM Mar 27, 2006
PharmaLive.com (press release), ...largest biotechnology company, today announced the US Food and Drug Administration (FDA) has approved every-three-week dosing of Aranesp(R) (darbepoetin alfa ...
Bad news for others, good news for Amgen Mar 26, 2006
Ventura County Star (subscription), ...said the dip in the anti-anemia drug's sales could be attributed to Amgen's Aranesp gaining market share. Aranesp, a longer-lasting ...
Amgen "outperform" Mar 20, 2006
newratings.com According to the analysts, the sales of Amgen’s Aranesp drug are unlikely to be adversely affected by this decision going forward.
Amgen Anemia Drug Achieves New Study Success Mar 15, 2006
International News Service, A phase II study of Amgen's Aranesp has shown that the anemia drug also improved symptoms in patients with symptomatic heart failure. ...
Amgen Says Phase 2 Study Shows Treatment Of Anemia With Aranesp ... Mar 13, 2006
Trading Markets, ...the world's largest biotechnology company, said Monday results from a Phase 2 study showed that treating anemia with the company's Aranesp drug in patients ...
Amgen CEO assesses generic threat Mar 1, 2006
MarketWatch Likewise, the company's patents on its other top-selling drugs, such as Aranesp, are not due to expire for several years. Epogen ...
Blue chips drop as investors step back for Fed Mar 27, 2006
ABC News Shares of Johnson & Johnson dropped after US regulators approved a new dosing regimen for anemia drug, Aranesp, made by rival Amgen Inc. ...
US Stocks Slide Before Fed Decision on Rates; Utilities Fall Mar 27, 2006
Bloomberg The US Food and Drug Administration approved Amgen's Aranesp anemia medication for use every three weeks, providing a more convenient dosing option for ...
Blue chips decline, investors edgy about Fed Mar 27, 2006
Reuters Shares of Johnson & Johnson (JNJ.N: Quote, Profile, Research) fell after US regulators approved a new dosing regimen for anemia drug, Aranesp, made by rival ...
Shares Fall in Slow Trading Ahead of Fed Rate Meeting Mar 27, 2006
New York Times, The Food and Drug Administration approved Amgen's Aranesp anemia medication for use every three weeks, providing a more convenient dosing option for patients ...
Demand to expand Mar 28, 2006
TMCnet Manufacturing also is being expanded at a cost of $1 billion in Puerto Rico to boost capacity for drugs produced there -- Epogen, Aranesp, Neupogen and Neulasta ...
Dow dips, Nasdaq up as US investors wary before Fed Mar 27, 2006
Jackson News-Tribune, Shares of Johnson & Johnson (NYSE:JNJ - news) dropped after US regulators approved a new dosing regimen for anemia drug, Aranesp, made by rival Amgen Inc. ...
Bayer dips on Schering concerns Mar 27, 2006
Investor's Business Daily (subscription) And Amgen (AMGN) seemed to get little mileage from an FDA announcement that allows for extended dosing of its Aranesp medication to treat chemotherapy-induced ...
Amgen "outperform" Mar 3, 2006
New Ratings ...patients. There is significant growth potential for Amgen’s Aranesp in CKD patients in the near to medium term, the analysts say. ...
Epoetin Alfa Improves Quality of Life in Patients Receiving ... Mar 10, 2006
Cancer Consultants (press release), ...transfusion requirements. More recently, similar results have been achieved with long acting Aranesp® (darbepoetin). The current ...
Survey: Oncologists pessimistic about MMA Mar 22, 2006
Monsters and Critics.com, ...co-payments and co-insurance will reduce cancer patients` access to erythropoiesis stimulating proteins, such as Johnson & Johnson`s Procrit and Amgen`s Aranesp ...
Glover leads at Bay Hill Mar 17, 2006
Pittsburgh Tribune-Review, Museeuw, widely recognized as the top one-day cyclist of the past decade, and the others are accused of possessing the endurance-boosting drugs EPO and Aranesp ...
Amgen "buy" Mar 20, 2006
newratings.com AACR meeting. The expected label expansion for Aranesp is unlikely to be a significant positive for Amgen, the analyst says. Banc ...
Early Treatment of Chemotherapy-Induced Anemia Linked with Greater ... Mar 17, 2006
Cancer Consultants (press release), ...need for blood transfusions. These medications include Aranesp® (darbepoetin alfa) and Procrit® (epoetin alfa). An issue that ...
Schaeffer's Daily Market Blog Features Amgen, Toyota Motor ... Mar 13, 2006
Business Wire (press release), The company stated that a Phase II study has shown that treating anemia with Aranesp in patients with heart failure was well-tolerated, effectively raised ...
Office-Based Oncologists Pessimistic About the Effect of Medicare ... Mar 22, 2006
PharmaLive.com (press release), ...and coinsurance will reduce cancer patients' access to erythropoiesis stimulating proteins (ESPs) such as Johnson & Johnson's Procrit and Amgen's Aranesp. ...
Glaxo, Gilead, Merck Part of Team to fight HIV and Amgen Anemia ... Mar 15, 2006
Financial News USA (press release), Amgen Inc.'s (Nasdaq:AMGN) anemia drug Aranesp improved symptoms in patients with heart failure in a small clinical trial, including the ability to walk, the ...
Drug cheats warned as Games draw near Mar 9, 2006
ABC Online, ...sinister though is the practice of blood doping, particularly the use of an artificial hormone known as EPO and the new drug known as Aranesp, whereby athletes ...
Amgen's "strategic intention" is to acquire - CEO Mar 1, 2006
Reuters ...over. Amgen sued Roche claiming Roche's drug Cera infringes on Amgen's patents for Epogen and its longer-lasting version Aranesp. ...
The Best-Selling Drugs In America Feb 27, 2006
Forbes Overall, drug sales grew 5.4% to $252 billion in 2005. But sales of biotech drugs like Amgen's Aranesp and Genentech's Rituxan grew 17% to $33 billion. ...
Only a quarter of Comm Games athletes to be drug tested Mar 9, 2006
ABC Online, The heart-related deaths of 10 cyclists between 2003 and 2005 raised suspicions that drug cheats had moved from EPO to the more potent Aranesp. ...
Biotechs take a stronghold on sales Mar 1, 2006
Newark Star Ledger, Amgen makes four of the top 20 drugs, including Aranesp for kidney-disease-related and chemotherapy-related anemia; Epogen, for anemia from chronic kidney ...
Eye On Stocks For Friday, March 13, 2006 Mar 10, 2006
Forbes Amgen (nasdaq: AMGN - news - people ) is expected to reveal additional Phase II data for Aranesp, a treatment for heart failure, on March 13. ...
US Drug Sales Increase 5.4% In 2005, Expected To Rise At That Rate ... Feb 27, 2006
Medical News Today (press release), Biotechnology drugs, such as Genentech's Rituxan cancer treatment and Amgen's Aranesp anemia treatment, experienced a 17.2% increase in sales, rising to $32.8 ...
Investigative Drug Aranesp (Darbepoetin) Effective for ... Dec 14, 2005
DG News ATLANTA, GA -- December 14, 2005 -- Treatment of chemotherapy-induced anemia with the investigative agent darbepoetin (Aranesp(R)) administered every 3 weeks ...
Darbepoetin Alfa (Aranesp) Data Suggests Major Response in Anemic ... Dec 16, 2005
DG News ATLANTA, GA -- December 16, 2005 -- Interim results from a phase 2, open-label study indicate that darbepotin alfa (Aranesp) 500 mcg taken Q3W appears to be ...
Benefits Of Aranesp Dosed Every Three Weeks For Chemotherapy ... Dec 12, 2005
Medical News Today (press release), ...company, today announced interim results from the first multi-center, randomized, double-blind, placebo-controlled, Phase 3 trial of Aranesp® (darbepoetin alfa ...
Updated Interim Aranesp(R) Phase 2 Data Suggest Major Response in ... Dec 11, 2005
Business Wire (press release), ...the world's largest biotechnology company, today announced updated interim data from a Phase 2 study evaluating the use of 500 mcg of Aranesp(R) (darbepoetin ...
Interim aranesp data suggest major response in anemic patients ... Dec 12, 2005
EurekAlert (press release), ...the world's largest biotechnology company, today announced updated interim data from a Phase 2 study evaluating the use of 500 mcg of Aranesp darbepoetin alfa ...
Aranesp® Effective in Low and Intermediate Risk Myelodysplastic ... Dec 7, 2005
Cancer Consultants (press release), Researchers from Italy have demonstrated that long-acting Aranesp (darbepoetin alfa) is as effective as Procrit® (epoetin alfa) for the treatment of patients ...
FDA Announcement: Aranesp, Epogen, Procrit Associated with Reports ... Dec 2, 2005
PharmaLive.com (press release), ...new prescribing information. Read the complete Dear Healthcare Professional regarding Aranesp letter below. The healthcare letters ...
Aranesp: pure red cell aplasia and severe anemia associated with ... Dec 4, 2005
Xagena.it, Amgen has informed Health Care Professionals that sections of the product prescribing information for Aranesp ( Darbepoetin alfa ) have been updated regarding ...
Neulasta® and Aranesp® Prevent Adverse Effects of Dose-Dense ... Nov 28, 2005
Cancer Consultants (press release), Treatment with Neulasta® (pegfilgrastim) and Aranesp® (darbepoetin alfa) safely and effectively prevented febrile neutropenia and anemia among women ...
Neulasta® and Aranesp® Provide Effective Hematopoietic Support ... Nov 21, 2005
Cancer Consultants (press release), ...from the Dana Farber Cancer Centerhave reported that the prophylactic administration of pegfilgrastim (Neulasta) and darbepoetin alfa (Aranesp) was effective ...
Aranesp® Effective in Myelodysplastic Syndromes Dec 2, 2005
Cancer Consultants (press release), According to a recent article published in the Annals of Oncology, Aranesp (darbepoetin afla) is effective in the treatment of anemia in patients with low or ...
Amgen Updates Product Prescribing Information for Aranesp ... Dec 2, 2005
DG News ...is informing health care professionals that sections of the product prescribing information for Aranesp (darbepoetin alfa) have been updated regarding the fact ...
Drug cuts transfusions in half for chemo patients Dec 15, 2005
Cancerfacts.com, It is the first large, multi-center, comparison trial of Aranesp® (darbepoetin alfa) administered every three weeks in cancer patients with anemia resulting ...
Amgen "neutral weight" Dec 14, 2005
New Ratings ...yesterday, the analyst mentions that the company recently presented key data for its supportive care agents for anemia and thrombocytopenia, Aranesp and AMG 531 ...
Amgen, J&J notify doctors on anemia drugs' disorder Dec 6, 2005
Ventura County Star (subscription), The advice is among changes to the prescribing information for doctors using the three drugs, Aranesp, Epogen and Procrit, the Food and Drug Administration ...
Drug increases hemoglobin in Myelodysplastic Syndrome Dec 13, 2005
MedIndia, Patients with Bone marrow disorder Myelodysplastic Syndrome (MDS), treated with 500 mcg of Aranesp (Darbepoetin alfa) for every three weeks found to improve ...
ASH Data Continue Building Dec 12, 2005
TheStreet.com Cramer's Take), the world's biggest biotech company, said patients with chemotherapy-induced anemia could still benefit from its anemia drug Aranesp even if ...
Amgen drug could offer option for platelet disease Dec 13, 2005
Ventura County Star (subscription), Amgen also reported study results from Aranesp, its anti-anemia drug. The results showed Aranesp helped increase hemoglobin in patients ...
Two Companies Issue Warnings on Anemia Drugs Dec 5, 2005
Newsinferno.com, ...about their anemia drugs. Amgen manufactures both Epogen and Aranesp, while Ortho Biotech makes Procrit. The drugs are approved ...
J&J, Amgen Warn Doctors on Anemia Drugs' Disorder (Update1) Dec 1, 2005
Bloomberg 1 (Bloomberg) -- Johnson & Johnson and Amgen Inc.'s anemia drugs Aranesp, Epogen and Procrit may have a risk of damaging red blood cells, known as aplasia, and ...
Alert Issued on Anemia Drugs Dec 2, 2005
Los Angeles Times, Johnson & Johnson and Amgen Inc.'s anemia drugs, Aranesp, Epogen and Procrit, may have a risk of damaging red blood cells in certain patients, US regulators ...
Amgen "outperform" Dec 1, 2005
New Ratings The analysts believe, however, that the sales of Amgen’s Aranesp would be boosted by an increasingly binary market, given the company’s competitive ...
Amgen initiated with "buy" Dec 16, 2005
New Ratings ...note published this morning, the analyst mentions that the performance of Amgen's core business remains robust, driven by the company's Aranesp, Neulasta and ...
New Medicare Claims Monitoring System for Epoetin, Darbepoetin Use Dec 9, 2005
Medscape (subscription) Centers for Medicare & Medicaid Services (CMS) policy for monitoring and coverage of erythropoietin (EPO; Epogen) or darbepoetin alfa (Aranesp) for treatment ...
J&J, Amgen Caution on Anemia Drugs Dec 1, 2005
TheStreet.com The warnings apply to Johnson & Johnson's Procrit and Amgen's Epogen and Aranesp, which are all designed to treat anemia, a condition marked by a low count of ...
Anemia in Lung Cancer Patients Often Undertreated Nov 30, 2005
Cancer Consultants (press release), Anemia can be treated by blood transfusions or one of the epoetins such as Procrit® (epoetin alfa) or Aranesp® (darbepoetin alfa). ...
Pharma Reformulates Dec 5, 2005
Chemical & Engineering News A strong performance from Amgen's second-generation erythropoieitin (EPO) product for anemia, Aranesp, helped propel the EPO class up the rankings, while ...
National Briefs Dec 2, 2005
New York Times, Their manufacturers, Johnson & Johnson and Amgen, have notified doctors that the drugs - Aranesp, Epogen and Procrit - should be discontinued if patients ...
Biotech Earnings Jump In Quarter Nov 21, 2005
Chemical & Engineering News ...$3.2 billion. Sales of Amgen’s anemia treatment Aranesp continued to grow in the quarter, rising 38% to $840 million. Enbrel, a ...
|
|
